This study included 95 patients with MSS colon cancer that had become resistant to chemo and had spread. They were treated with what is known as immune checkpoint inhibitor PD-1/PD-L1 targeted therapy. It helps the"To our knowledge, this is the largest study to evaluate the impact of PD-1/PD-L1 targeting on patient response as stratified by site of metastatic disease," said researcher Dr.
The median time of disease progression for patients whose cancer had not spread to the liver was four months, compared to one and a half months for those whose cancer had spread to the liver, the study found.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Forbes - 🏆 394. / 53 Read more »